These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 19221637

  • 1. Molecule of the month. Dirucotide.
    Drug News Perspect; 2008 Dec; 21(10):572. PubMed ID: 19221637
    [No Abstract] [Full Text] [Related]

  • 2. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
    Darlington C.
    Curr Opin Mol Ther; 2007 Aug; 9(4):398-402. PubMed ID: 17694453
    [Abstract] [Full Text] [Related]

  • 3. Specific immunotherapy: one size does not fit all.
    Genain CP, Zamvil SS.
    Nat Med; 2000 Oct; 6(10):1098-100. PubMed ID: 11017135
    [No Abstract] [Full Text] [Related]

  • 4. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis.
    Correale J, Fiol M.
    Curr Opin Mol Ther; 2009 Aug; 11(4):463-70. PubMed ID: 19649992
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
    Katsara M, Deraos G, Tselios T, Matsoukas MT, Friligou I, Matsoukas J, Apostolopoulos V.
    J Med Chem; 2009 Jan 08; 52(1):214-8. PubMed ID: 19072222
    [Abstract] [Full Text] [Related]

  • 6. DNA plasmid vaccination for multiple sclerosis.
    Stüve O, Eagar TN, Frohman EM, Cravens PD.
    Arch Neurol; 2007 Oct 08; 64(10):1385-6. PubMed ID: 17923622
    [No Abstract] [Full Text] [Related]

  • 7. Altered peptide ligands and MS treatment.
    Conlon P, Steinman L.
    Science; 2002 Jun 07; 296(5574):1801-2; author reply 1801-2. PubMed ID: 12053936
    [No Abstract] [Full Text] [Related]

  • 8. NBI-5788 Neurocrine.
    Darlington CL.
    Curr Opin Investig Drugs; 2005 Jul 07; 6(7):747-51. PubMed ID: 16044672
    [Abstract] [Full Text] [Related]

  • 9. Is there a place for 'immuno' in the immunotherapy of multiple sclerosis?
    Forsthuber TG, Muraro P.
    Immunotherapy; 2009 May 07; 1(3):329-31. PubMed ID: 20635950
    [No Abstract] [Full Text] [Related]

  • 10. MRI as an outcome in multiple sclerosis clinical trials.
    Tenser RB.
    Neurology; 2009 Dec 01; 73(22):1933-4; author reply 1934. PubMed ID: 19949044
    [No Abstract] [Full Text] [Related]

  • 11. Mitoxantrone: multiple sclerosis: too many serious adverse effects.
    Prescrire Int; 2008 Feb 01; 17(93):17. PubMed ID: 18354876
    [No Abstract] [Full Text] [Related]

  • 12. Antibodies against a class II HLA-peptide complex raised by active immunization of mice with antigen mimicking peptides.
    Dam-Tuxen R, Riise E.
    Scand J Immunol; 2009 Aug 01; 70(2):93-100. PubMed ID: 19630914
    [Abstract] [Full Text] [Related]

  • 13. Futility studies: spending a little to save a lot.
    Schwid SR, Cutter GR.
    Neurology; 2006 Mar 14; 66(5):626-7. PubMed ID: 16534098
    [No Abstract] [Full Text] [Related]

  • 14. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
    Tenser RB, Polman CH.
    Neurology; 2009 Mar 31; 72(13):1191-2; author reply 1192. PubMed ID: 19332703
    [No Abstract] [Full Text] [Related]

  • 15. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N.
    Neurology; 2009 Feb 24; 72(8):686-7. PubMed ID: 19237696
    [No Abstract] [Full Text] [Related]

  • 16. MRI as an outcome in multiple sclerosis clinical trials.
    Sormani MP, Filippi M, De Stefano N, MAGNIMS Steering Committee, Ebers G, Daumer M.
    Neurology; 2009 Dec 01; 73(22):1932; author reply 1932-3. PubMed ID: 19949043
    [No Abstract] [Full Text] [Related]

  • 17. Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis.
    Menge T, Schloot NC, Schott M, Hemmer B, Wiendl H, Roden M, Hartung HP, Kieseier BC.
    Neurology; 2009 Sep 15; 73(11):900-2. PubMed ID: 19752459
    [No Abstract] [Full Text] [Related]

  • 18. Antigen-specific therapies in multiple sclerosis.
    Giacomini PS, Bar-Or A.
    Expert Opin Emerg Drugs; 2009 Sep 15; 14(3):551-60. PubMed ID: 19708820
    [Abstract] [Full Text] [Related]

  • 19. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
    Yeh EA, Weinstock-Guttman B.
    Neurology; 2009 Jun 16; 72(24):2064-5. PubMed ID: 19439721
    [No Abstract] [Full Text] [Related]

  • 20. [Update: treatment of multiple sclerosis].
    Kümpfel T, Hohlfeld R.
    MMW Fortschr Med; 2009 Mar 26; 151(13):70-2. PubMed ID: 19504824
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.